Benzylpenicillin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Benzylpenicillin: From Bacterial Infections to Pericoronitis
One-Sentence Summary
Benzylpenicillin (penicillin G) is an injectable antibiotic originally used for streptococcal, pneumococcal, meningococcal and staphylococcal infections, as well as endocarditis and anthrax. The TxGNN model predicts it may be effective for pericoronitis (score 99.4%), but no clinical trials and no publications currently support this prediction. It is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Streptococcal infection, meningococcal infection, pneumococcal meningitis, staphylococcal infection, endocarditis, anthrax, and other bacterial infections (the Singapore licence record contains no indication text; this list comes from the knowledge graph) |
| Predicted New Indication | Pericoronitis |
| TxGNN Prediction Score | 99.36% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, benzylpenicillin is a penicillin-class beta-lactam antibiotic. Its efficacy against streptococcal and other susceptible gram-positive infections is established, and mechanistically it may be applicable to pericoronitis.
Pericoronitis is a mixed infection (streptococci and anaerobes) of the tissue around a partially erupted tooth, usually a wisdom tooth. Many of these organisms are susceptible to penicillins, so the prediction is biologically plausible. The high score appears to reflect this similarity to bacterial infections already on the drug's profile.
There are practical concerns. Benzylpenicillin is given by injection only and has poor oral bioavailability, which makes it an awkward fit for a mainly outpatient dental condition. The data compiled for this report contain no trial or literature evidence, so the 99.4% score should be read as a model output, not as proof of efficacy.
Other top-ranked predictions are weaker still. Most are not primarily bacterial conditions: gingival recession, canker sore, ulcerative stomatitis, chemotherapy-induced oral mucositis, denture stomatitis (Candida-driven) and gingival leukoplakia. Cat-scratch disease (an intracellular organism not typically covered by beta-lactams) and chronic ethmoidal sinusitis are also poorly matched. Conjunctivitis is plausible for susceptible bacteria but has only indirect evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
For the top prediction (pericoronitis), currently no related literature is available.
For reference, the only prediction with any retrieved literature is conjunctivitis (rank 8). None of it is a clinical study of benzylpenicillin in human conjunctivitis:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33789741 | 2021 | Case series | J Med Case Rep | Clinical presentation of seven infants with congenital syphilis in Lusaka, Zambia |
| 17496706 | 2007 | Case report | Eye Contact Lens | Severe microbial keratitis in a patient with keratoglobus and vernal keratoconjunctivitis; poor response to medical management |
| 2936791 | 1986 | Diagnostic study | J Allergy Clin Immunol | Lymphocyte transformation test for occupational drug allergy (bacampicillin, alprenolol, quinidine) |
| 453797 | 1979 | Microbiology | Antibiotiki | Staphylococci isolated from 79.2% of patients with eye disease; antibiotic susceptibility profiles |
| 6364656 | 1983 | Animal study | Zh Mikrobiol Epidemiol Immunobiol | Reduced neutrophil phagocytic function in experimental staphylococcal and E. coli keratoconjunctivitis |
| 2704058 | 1989 | Veterinary PK | J Vet Pharmacol Ther | Penicillin concentrations in bovine conjunctival sac fluid after topical application |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN00682P | PENICILLIN G SODIUM SANDOZ 5,000,000 IU/VIAL | Powder for solution for injection | Not stated in the licence record |
Manufacturer: Sandoz GmbH. Only the injectable route is registered in Singapore.
Safety Considerations
- Contraindication-related conditions (from the knowledge graph, not label text): kidney disease, pyoureter, Clostridium difficile colitis, perinatal necrotizing enterocolitis, infectious mononucleosis, chronic Epstein-Barr virus infection syndrome.
- Drug Interactions: 21 interactions were found in total. Among those listed, the most important is:
- Major: Methotrexate
- Moderate: Warfarin, dicoumarol, ethinylestradiol, mycophenolic acid, chloramphenicol, tetracycline-class antibiotics (doxycycline, minocycline, tetracycline, demeclocycline, oxytetracycline), picosulfuric acid, radioactive iodide (I-123, I-131)
- Minor: Clarithromycin, erythromycin
- Level not graded: Salbutamol, acyclovir, gentamicin, levothyroxine
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The pericoronitis prediction is biologically plausible because penicillin-susceptible streptococci and anaerobes are involved. However, it rests on a model score alone (L5), with no trials or literature. The injection-only product is also poorly suited to this condition. The other top predictions are mechanistically weak.
To proceed, the following is needed:
- Clinical and literature evidence for benzylpenicillin (or other penicillins) in pericoronitis
- Comparison with established oral antibiotic options for dental infections
- Package insert warnings and contraindications from the HSA record, and the approved indication text
- Mechanism of action data
- Assessment of route suitability (injection-only product) and of antibiotic stewardship and allergy risk
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.